C B Westphalen
Overview
Explore the profile of C B Westphalen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mosele M, Westphalen C, Stenzinger A, Barlesi F, Bayle A, Bieche I, et al.
Ann Oncol
. 2025 Feb;
PMID: 39984357
No abstract available.
2.
3.
Westphalen C, Martins-Branco D, Beal J, Cardone C, Coleman N, Schram A, et al.
Ann Oncol
. 2024 Aug;
35(11):936-953.
PMID: 39187421
Background: Advances in precision oncology led to approval of tumour-agnostic molecularly guided treatment options (MGTOs). The minimum requirements for claiming tumour-agnostic potential remain elusive. Methods: The European Society for Medical...
4.
van de Haar J, Roepman P, Andre F, Balmana J, Castro E, Chakravarty D, et al.
Ann Oncol
. 2024 Aug;
35(11):954-967.
PMID: 39112111
Background: Genomic tumour profiling has a crucial role in the management of patients with solid cancers, as it helps selecting and prioritising therapeutic interventions based on prognostic and predictive biomarkers,...
5.
Mosele M, Westphalen C, Stenzinger A, Barlesi F, Bayle A, Bieche I, et al.
Ann Oncol
. 2024 Jun;
35(7):588-606.
PMID: 38834388
Background: Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour...
6.
Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, Andre T, et al.
Ann Oncol
. 2024 May;
35(7):643-655.
PMID: 38777726
Background: POLE and POLD1 proofreading deficiency (POLE/D1pd) define a rare subtype of ultramutated metastatic colorectal cancer (mCRC; over 100 mut/Mb). Disease-specific data about the activity and efficacy of immune checkpoint...
7.
WEISS L, Fischer L, Heinemann V, Gieseler F, Hoehler T, Mayerle J, et al.
ESMO Open
. 2024 Mar;
9(4):102944.
PMID: 38503144
Background: Over the past two decades, our group has conducted five multicenter trials focusing on first-line systemic therapy for patients with advanced pancreatic cancer. The current pooled analysis was designed...
8.
Lim K, Westphalen C, Mateo J, Lambertini M, Amaral T
ESMO Open
. 2023 Nov;
8(6):102059.
PMID: 37925847
No abstract available.
9.
Westphalen C, Federer-Gsponer J, Pauli C, Karapetyan A, Chalabi N, Duran-Pacheco G, et al.
ESMO Open
. 2023 Nov;
8(6):102035.
PMID: 37922692
Background: Patients with unfavorable carcinoma of unknown primary origin (CUP) have an extremely poor prognosis of ∼1 year or less, stressing the need for more tailored treatments, which are currently...
10.
Lim K, Westphalen C, Berghoff A, Cardone C, Connolly E, Guven D, et al.
ESMO Open
. 2023 Sep;
8(5):101625.
PMID: 37659290
No abstract available.